SCHEMBL505220

SCHEMBL505220

CC(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.69
TP53 P04637 1/20 0.69
MPO P05164 1/20 0.68
MAPT P10636 5/20 0.68
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
HTT P42858 1/20 0.68
RAB9A P51151 1/20 0.68
ALDH1A1 P00352 4/20 0.66
L3MBTL1 Q9Y468 2/20 0.65
LMNA P02545 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.63
GAA P10253 3/20 0.62
NPSR1 Q6W5P4 2/20 0.62
XBP1 P17861 1/20 0.62
KDM4E B2RXH2 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
IDH1 O75874 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30022965 1.00 RXFP1 (0.69) RXFP1TP53MPOMAPTMEN1
Formic Acid SCHEMBL27757156 0.94 RXFP1 (0.63) RXFP1TP53MPOMAPTMEN1
SCHEMBL28017040 0.86 L3MBTL1 (0.61) RXFP1TP53MPOMAPTMEN1
SCHEMBL9761962 0.86 L3MBTL1 (0.61) RXFP1TP53MPOMAPTMEN1
SCHEMBL5536500 0.86 L3MBTL1 (0.61) RXFP1TP53MPOMAPTMEN1
SCHEMBL30101230 0.85 KMT2A (0.90) TP53MAPTMEN1KMT2AHTT
SCHEMBL5597699 0.85 KMT2A (0.90) TP53MAPTMEN1KMT2AHTT
SCHEMBL25472097 0.84 MPO (0.72) RXFP1TP53MPOMAPTMEN1
SCHEMBL2096021 0.84 MAPT (0.70) TP53MAPTMEN1KMT2AHTT
SCHEMBL4548162 0.84 KMT2A (0.87) TP53MAPTMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115232019-B Synthesis method of 3-acetamido benzotrifluoride compound 闽江学院 2023-10-27 CN claimed
CN-111526877-B Compounds and compositions for IRE1 inhibition 奥普提卡拉公司 2023-08-25 CN claimed
CN-115232019-A Synthetic method of 3-acetamido benzotrifluoride compound 闽江学院 2022-10-25 CN claimed
CN-109563043-A SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 葛兰素史密斯克莱知识产权发展有限公司 2019-04-02 CN claimed
CN-104557589-A Preparation method of N-(1,1'-diaryl) substituted amide derivative UNIV TIANJIN 2015-04-29 CN claimed
EP-1885717-B1 SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES MAX DELBRUECK CENTRUM (DE) 2011-08-17 EP claimed
CN-102093229-A Preparation method of 4-nitro-3-trifluoromethylaniline JUNKAI TIANJIN CHEMICAL CO LTD 2011-06-15 CN claimed
US-20080194563-A1 Shp-2 Inhibitors, Pharmaceutical Compositons Comprising Them and Their Use For Treating Phosphatase-Mediated Diseases MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2008-08-14 US claimed
EP-1885717-A1 SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) 2008-02-13 EP claimed
WO-2006128909-A1 SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES Max-Delbrück-Centrum für Molekulare Medizin (DE) 2006-12-07 WO claimed
CN-113679717-B Methods for inhibiting fascin 康奈尔大学 2026-05-22 CN disclosed
US-12623942-B2 Method for extracting salts and temperature- regenerated extracting composition ADIONICS (FR) 2026-05-12 US disclosed
CN-113292128-B Apparatus and method for desalting water by thermal deionization and liquid phase ion extraction 艾迪奥尼克斯公司 2024-07-05 CN disclosed
CN-113462278-B Varnish composition, method for producing polyimide resin, and additive 东京应化工业株式会社 2024-06-07 CN disclosed
US-20230382775-A1 METHOD FOR EXTRACTING SALTS AND TEMPERATURE-REGENERATED EXTRACTING COMPOSITION ADIONICS (FR) 2023-11-30 US disclosed
US-4331821-A ULTRAVIOLET RADIATION OF A VAPORIZED ALKYLBENZEN AND HALOGEN GAS MIXTURE BAYER AKTIENGESELLSCHAFT (DE) 1982-05-25 US disclosed
US-4302599-A Process for nitrating anilides SCHERING CORPORATION (US) 1981-11-24 US disclosed
US-4210589-A CYCLIZATION STAUFFER CHEMICAL COMPANY (US) 1980-07-01 US disclosed
US-4136019-A ORGANIC TRIFLUORO COMPOUND AS SELECTIVITY AGENT, FATTY ACID COLLECTOR UNITED STATES BORAX & CHEMICAL CORP. (US) 1979-01-23 US disclosed
US-4110105-A Aromatic N-substituted halo-substituted-2-pyrrolidinones and their utility as herbicides STAUFFER CHEMICAL COMPANY (US) 1978-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194563-A1 Shp-2 Inhibitors, Pharmaceutical Compositons Comprising Them and Their Use For Treating Phosphatase-Mediated Diseases PTPN2, PTPRJ, PTPRS RXFP1 3717/4885TP53 231/4885MPO 3346/4885
US-12623942-B2 Method for extracting salts and temperature- regenerated extracting composition POLQ, NONO, AQP3 RXFP1 2302/4885TP53 2050/4885MPO 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.